GILD - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 24, 2026

4.0/10

Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Pricing was impacted by the U.S. Medicare Part D program redesign, affecting average realized prices in key segments like HIV and Liver Disease.. Ongoing litigation across multiple fronts (antitrust, patent, product liability, qui tam) presents a significant, unquantifiable risk to financial condition and results.. Increased total revenues by 2%

Top Concerns

!Significant R&D impairments ($4.8 billion in 2024 and $590 million in 2025) suggest high uncertainty and potential overvaluation of intangible assets related to drug development.
!Change in revenue disclosure for major customers could obscure trends if not analyzed carefully.
!Ongoing litigation across multiple fronts (antitrust, patent, product liability, qui tam) presents a significant, unquantifiable risk to financial condition and results.
!The company is actively defending intellectual property rights against generic challenges, indicating potential future revenue impacts if these disputes are lost.
!Regulatory and Pricing Pressures (high)

Top Positives

+Revenue growth was modest at 2%, driven by strong performance in HIV and Liver Disease segments, but offset by declining Veklury sales.
+Net income saw a significant increase, primarily due to the absence of large one-time IPR&D expenses and impairment charges from the prior year, rather than core operational improvements.
+The HIV franchise remains a key driver of growth, with substantial increases in Biktarvy and Descovy sales.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

6.0/10

Management tone is confidently optimistic with focus on product gross margin remained relatively flat compared to the prior year..

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

6.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is elevated.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows regulatory and pricing pressures as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

7.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.